These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 26516223)

  • 1. Immunomodulation: checkpoint blockade etc.
    Curry WT; Lim M
    Neuro Oncol; 2015 Nov; 17 Suppl 7(Suppl 7):vii26-vii31. PubMed ID: 26516223
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radiotherapy combined with immune checkpoint blockade immunotherapy: Achievements and challenges.
    Teng F; Kong L; Meng X; Yang J; Yu J
    Cancer Lett; 2015 Aug; 365(1):23-9. PubMed ID: 25980820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Checkpoint blockade immunotherapy for cancer comes of age.
    Brower V
    J Natl Cancer Inst; 2015 Mar; 107(3):. PubMed ID: 25745014
    [No Abstract]   [Full Text] [Related]  

  • 4. The dawn of "immune-revolution" in children: early experiences with checkpoint inhibitors in childhood malignancies.
    Lucchesi M; Sardi I; Puppo G; Chella A; Favre C
    Cancer Chemother Pharmacol; 2017 Dec; 80(6):1047-1053. PubMed ID: 29067473
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Inhibitors.
    Haanen JB; Robert C
    Prog Tumor Res; 2015; 42():55-66. PubMed ID: 26382943
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy.
    Adachi K; Tamada K
    Cancer Sci; 2015 Aug; 106(8):945-50. PubMed ID: 25981182
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SnapShot: Immune Checkpoint Inhibitors.
    Abril-Rodriguez G; Ribas A
    Cancer Cell; 2017 Jun; 31(6):848-848.e1. PubMed ID: 28609660
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New checkpoint inhibitors ride the immunotherapy tsunami.
    Mullard A
    Nat Rev Drug Discov; 2013 Jul; 12(7):489-92. PubMed ID: 23812256
    [No Abstract]   [Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitors: Basics and Challenges.
    Li B; Chan HL; Chen P
    Curr Med Chem; 2019; 26(17):3009-3025. PubMed ID: 28782469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perspectives for immunotherapy in endocrine cancer.
    Latteyer S; Tiedje V; Schilling B; Führer D
    Endocr Relat Cancer; 2016 Oct; 23(10):R469-84. PubMed ID: 27485460
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Poxvirus-based active immunotherapy synergizes with CTLA-4 blockade to increase survival in a murine tumor model by improving the magnitude and quality of cytotoxic T cells.
    Foy SP; Mandl SJ; dela Cruz T; Cote JJ; Gordon EJ; Trent E; Delcayre A; Breitmeyer J; Franzusoff A; Rountree RB
    Cancer Immunol Immunother; 2016 May; 65(5):537-49. PubMed ID: 26961085
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predictive biomarkers in PD-1/PD-L1 checkpoint blockade immunotherapy.
    Meng X; Huang Z; Teng F; Xing L; Yu J
    Cancer Treat Rev; 2015 Dec; 41(10):868-76. PubMed ID: 26589760
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunotherapy Toxicities.
    Sanchez K; Page DB; Urba W
    Surg Oncol Clin N Am; 2019 Jul; 28(3):387-401. PubMed ID: 31079795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Programmed death 1 immune checkpoint inhibitors.
    Trivedi MS; Hoffner B; Winkelmann JL; Abbott ME; Hamid O; Carvajal RD
    Clin Adv Hematol Oncol; 2015 Dec; 13(12):858-68. PubMed ID: 27058852
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapeutic Development of Immune Checkpoint Inhibitors.
    Wang J; Yang T; Xu J
    Adv Exp Med Biol; 2020; 1248():619-649. PubMed ID: 32185726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Checkpoint blocking antibodies in cancer immunotherapy.
    Kyi C; Postow MA
    FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Practical Approaches to Immunotherapy in the Clinic.
    Agarwala SS
    Semin Oncol; 2015 Dec; 42 Suppl 3():S20-7. PubMed ID: 26598056
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for anti-OX40 cancer immunotherapy.
    Aspeslagh S; Postel-Vinay S; Rusakiewicz S; Soria JC; Zitvogel L; Marabelle A
    Eur J Cancer; 2016 Jan; 52():50-66. PubMed ID: 26645943
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Introduction.
    Liu J; Xu J
    Adv Exp Med Biol; 2020; 1248():1-6. PubMed ID: 32185704
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combinations with checkpoint inhibitors at wavefront of cancer immunotherapy.
    Cully M
    Nat Rev Drug Discov; 2015 Jun; 14(6):374-5. PubMed ID: 26027531
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.